Zytostatika-assoziierte Toxizitäten in der geriatrischen Onkologie

Chapter
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Zytostatika sind wichtige Bausteine für die Krebstherapie. Veränderte Organfunktionen, Komorbiditäten und Begleitmedikationen beeinflussen das Toxizitätsprofil von Zytostatika bei älteren Patienten. Die Studienlage zur Altersspezifität von Zytostatikatoxizität ist limitiert. Ältere Patienten sind in vielen klinischen Studien nicht repräsentativ vertreten. Für die meisten Zytostatika sind bei fehlenden signifikanten Einschränkungen der Organfunktionen keine altersspezifisch erhöhten Toxizitätsraten beschrieben. Letztlich obliegt es der klinischen Erfahrung eines interdisziplinären onkologischen Teams, eine Abwägung zwischen Toxizitätsrisiko mit drohender Lebensqualitätseinschränkung auf der einen und Effektivität einer Zytostatikatherapie auf der anderen Seite vorzunehmen. In diesem Kapitel werden Besonderheiten des geriatrischen Patienten im Hinblick auf die Toxizität von Zytostatika einschließlich moderner zielgerichteter Therapien dargelegt.

Literatur

  1. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32CrossRefPubMedGoogle Scholar
  2. Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA (2016) Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial. J Clin Oncol 34(6):581–587CrossRefPubMedGoogle Scholar
  3. Anía BJ, Suman VJ, Fairbanks VF et al (1997) Incidence of anemia in older people: an epidemiologic study in a well defined population. J Am Geriatr Soc 45:825CrossRefPubMedGoogle Scholar
  4. Balducci L, Corcoran MB (2000) Antineoplastic chemotherapy of the older cancer patient. Hematol Oncol Clin North Am 14:193–212CrossRefPubMedGoogle Scholar
  5. Biganzoli L, Lichtman S, Michel JP, Papamichael D, Quoix E, Walko C, Aapro M (2015) Oral single-agent chemotherapy in older patients with solid tumours: A position paper from the International Society of Geriatric Oncology (SIOG). Eur J Cancer 51(17):2491–500CrossRefPubMedGoogle Scholar
  6. Biganzoli L, Aapro M, Loibl S, Wildiers H, Brain E (2016) Taxanes in the treatment of breast cancer: have we better defined their role in older patients? A positive paper from a SIOG Task Force. Cancer Treat Rev 14:1040Google Scholar
  7. Bokemeyer C, Perry MC (1999) Hepatotoxizität. In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium internistische Onkologie. Springer, Berlin/Heidelberg/New YorkGoogle Scholar
  8. Brom RRH van den, van Es SC, Leliveld AM et al (2016) Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma. Cancer Treat Rev 46:63–72Google Scholar
  9. Chavez-MacGregor M, Uhang N, Buchholz TA et al (2013) Trastuzumab-realted cardiotoxicity among oder patients with breast cancer. J Clin Oncol 31:4222–4228CrossRefPubMedPubMedCentralGoogle Scholar
  10. Cockroft DW, Galut MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31–41Google Scholar
  11. Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, Le DT, Lipson EJ, Glezerman IG, Wolchok J, Cornell LD, Feldman P, Stokes MB, Zapata SA, Hodi FS, Ott PA, Yamashita M, Leaf DE (2016) Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90(3):638–647CrossRefPubMedPubMedCentralGoogle Scholar
  12. Cosmai L, Gallieni M, Porta C (2015) Renal toxicity of anticancer agents targeting HER2 and EGFR. J Nephrol 28(6):647–657CrossRefPubMedGoogle Scholar
  13. Decoster L, Van Puyvelde K, Mohile S, Wedding U, Basso U, Colloca G, Rostoft S, Overcash J, Wildiers H, Steer C, Kimmick G, Kanesvaran R, Luciani A, Terret C, Hurria A, Kenis C, Audisio R, Extermann M (2015) Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol 26(2):288–300CrossRefPubMedGoogle Scholar
  14. Dranitsaris G, Lacouture ME (2014) Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine. Breast Cancer Res Treat 147(3):631–638CrossRefPubMedPubMedCentralGoogle Scholar
  15. Eisen T, Oudard S, Szczylik C et al (2008) Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 100:1454–1463CrossRefPubMedPubMedCentralGoogle Scholar
  16. Eklund JW, Trifilio S, Mulcahy MF (2005) Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park) 19(8):1057–1063Google Scholar
  17. Elias R, Morales J, Rehman Y, Khurshid H (2016) Immune checkpoint inhibitors in older adults. Curr Oncol Rep 18:47CrossRefPubMedGoogle Scholar
  18. Engert A, Ballova V, Haverkamp H, Pfistner B, Josting A, Dühmke E, Müller-Hermelink K, Diehl V (2005) Hodgkin’s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin’s Study Group. J Clin Oncol 23(22):5052–5060CrossRefPubMedGoogle Scholar
  19. Extermann M, Bonetti M, Sledge GW et al (2004) MAX2 – a convenient index to estimate the average per paitent risk for chemotherapy toxicity; validation in ECOG trials. Eur J Cancer 40(8):1193–1198CrossRefPubMedGoogle Scholar
  20. Extermann M, Boler I, Reich RR et al (2012) Predicting the risk of chemotherapy toxizity in older patients: the Chemotherapy Risk Assessment Scale for High-age patients (CRASH) score. Cancer 118:3377–3386CrossRefPubMedGoogle Scholar
  21. Fuchs CS, Moore MR, Harker G et al (2003) Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21:807CrossRefPubMedGoogle Scholar
  22. Goede V, Bahlo J, Chataline V, Eichhorst B, Dürig J, Stilgenbauer S, Kolb G, Honecker F, Wedding U, Hallek M (2016) Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: results of the CLL9 trial of the German CLL study group. Leuk Lymphoma 57:789–796CrossRefPubMedGoogle Scholar
  23. Graff JN, Baciarello G, Armstrong AJ, Higano CS, Iversen P, Flaig TW, Forer D, Parli T, Phung D, Tombal B, Beer TM, Sternberg CN (2016) Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol 27(2):286–294CrossRefPubMedGoogle Scholar
  24. Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ, Young J (2015) The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol 26(6):1091–1101CrossRefPubMedGoogle Scholar
  25. Hardy D, Liu CC, Cormier JN et al (2010) Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer. Ann Oncol 21:1825CrossRefPubMedPubMedCentralGoogle Scholar
  26. Hershman DL, McBride RB, Eisenberger A et al (2008) Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. J Clin Oncol 26:3159CrossRefPubMedGoogle Scholar
  27. Hershman DL, Till C, Wright JD et al (2016) Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group clinical trials. J Clin Oncol 34(25):3014–3022CrossRefPubMedPubMedCentralGoogle Scholar
  28. Hulin Ce, Belch A, Shustik C, Petrucci MT, Duehrsen U et al (2016) Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial. J Clin Oncol. pii: JCO667295. [Epub vor Druck]Google Scholar
  29. Hurria A, Togawa K, Mohile SG et al (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29:2457–3465Google Scholar
  30. Hurria A, Wildes T, Blair SL et al (2014) Senior adult oncology, version 2.2014: clinical practice guidelines in oncology. J Natl Compr Canc Netw 12:82–126CrossRefPubMedGoogle Scholar
  31. Hurria A, Mohile S, Gajra A et al (2016) Validation for a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol 34:2366–2371CrossRefPubMedPubMedCentralGoogle Scholar
  32. Hutson TE, Bukowski RM, Rini BI et al (2014) Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer 110:1125–1132CrossRefPubMedPubMedCentralGoogle Scholar
  33. Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F et al (2016) Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget.  https://doi.org/10.18632/oncotarget.11657 [Epub vor Druck]
  34. Kaymakcalan MD, Xie W, Albiges L, North SA, Kollmannsberger CK, Smoragiewicz M, Kroeger N, Wells JC, Rha SY, Lee JL, McKay RR, Fay AP, De Velasco G, Heng DY, Choueiri TK (2016) Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer 122(3):411–419CrossRefPubMedGoogle Scholar
  35. Kelly CM, Power DG, Lichtman SM (2014) Targeted therapy in older patients with solid tumors. J Clin Oncol 32(24):2635–2646CrossRefPubMedGoogle Scholar
  36. Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, Kaneda H, Nishina S, Tsurutani J, Fujiwara K, Nomura M, Yamazoe Y, Chiba Y, Nishida S, Tamura T, Nakagawa K (2014) Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS One 9(7):e101902.  https://doi.org/10.1371/journal.pone.0101902
  37. Kleeberg UR, Linde H, Günther G, Tessen HW, Kersting M (2016) Bendamustin-rituximab combination is a safe and effective, ambulatory treatment for elderly patients with chronic lymphocytic leukemia: retrospective real-world analysis by age from a German registry and review of the literature. Anticancer Res 36(6):2827–2838PubMedGoogle Scholar
  38. Kumar A, Soares HP, Balducci L et al (2007) Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute sponsored cooperative groups. J Clin Oncol 25:1272CrossRefPubMedGoogle Scholar
  39. Launay-Vacher V, Aapro M, De Castro G Jr, Cohen E, Deray G, Dooley M, Humphreys B, Lichtman S, Rey J, Scotté F, Wildiers H, Sprangers B (2015) Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). Ann Oncol 26(8):1677–1684CrossRefPubMedGoogle Scholar
  40. Lichtman SM (2016) Systemic chemotherapy for cancer in elderly persons. www.Uptodate.com. Zugegriffen am 18.10.2016
  41. Lichtman SM, Cirrincione CT, Hurria A et al (2016) Effect of pretreatment renal function on treatment and clinical outcomes in the adjuvant treatment of older women with breast cancer: Alliance A171201, an ancillary study of CALGB/CTSU 49907. J Clin Oncol 34:699CrossRefPubMedPubMedCentralGoogle Scholar
  42. Lipp HP, Bokemeyer C, Koeppen S (2014) Begleitmaßnahmen bei definierter medikamentöser Therapie: Nephrotoxizität. http://www.onkodin.de/e6/e100876/e100882/. Zugegriffen am 18.10.2016
  43. Loh KP, Janelsins MC, Mohile SG et al (2016) Chemotherapy-related cognitive impairment in older patients with cancer. J Geriatr Oncol 7:270–280CrossRefPubMedPubMedCentralGoogle Scholar
  44. Martell RE, Peterson BL, Cohen HJ, Petros WP, Rai KR, Morrison VA, Elias L, Shepherd L, Hines J, Larson RA, Schiffer CA, Hurwitz HI (2002) Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. Cancer Chemother Pharmacol 50(1):37–45CrossRefPubMedGoogle Scholar
  45. Martinez-Tapia C, Canoui-Poitrine F, Bastuji-Garin S, Soubeyran P, Mathoulin-Pelissier S, Tournigand C, Paillaud E, Laurent M, Audureau E, ELCAPA Study Group (2016) Optimizing the G8 screening tool for older patients with cancer: diagnostic performance and validation of a six-item version. Oncologist 21(2):188–195CrossRefPubMedPubMedCentralGoogle Scholar
  46. Monfardini S, Sorio R, Boes GH, Kaye S, Serraino D (1995) Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new-drug-development studies. Cancer 76(2):333–338CrossRefPubMedGoogle Scholar
  47. Muss HB, Berry DA, Cirrincione C et al (2007) Toxicity of older and younger patients treated with adjuvant chemotherapy for node-postivie breast cancer: the cancer and leukemia group B experience. J Clin Oncol 25:3699–3704CrossRefPubMedGoogle Scholar
  48. Nagele EP, Han M, Acharya NK et al (2013) Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease. PLoS One 8:e60726CrossRefPubMedPubMedCentralGoogle Scholar
  49. NCCN National Comprehensive Cancer Network (2016) NCCN clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Zugegriffen am 19.10.2016
  50. Nishijima TF, Muss HB, Shachar SS, Moschos SJ (2016) Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis. Cancer Treat Rev 45:30–37CrossRefPubMedGoogle Scholar
  51. Palumbo A, Bringhen S, Mateos MV et al (2015) Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 125:2068–2074CrossRefPubMedPubMedCentralGoogle Scholar
  52. Papamichael D, Audisio RA, Glimelius B, de Gramont A, Glynne-Jones R, Haller D, Köhne CH, Rostoft S, Lemmens V, Mitry E, Rutten H, Sargent D, Sastre J, Seymour M, Starling N, Van Cutsem E, Aapro M (2015) Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol 26(3):463–476CrossRefPubMedGoogle Scholar
  53. Pawelec G, Derhovanessian E, Larbi A (2010) Immunosenescence and cancer. Crit Rev Oncol Hematol 75:165–172CrossRefPubMedGoogle Scholar
  54. Peerzada MM, Spiro TP, Daw H (2010) Pulmonary toxicities of biologics: a review. Anticancer Drugs 21:131–139CrossRefPubMedGoogle Scholar
  55. Petit-Monéger A, Rainfray M, Soubeyran P, Bellera CA, Mathoulin-Pélissier S (2016) Detection of frailty in elderly cancer patients: improvement of the G8 screening test. J Geriatr Oncol 7(2):99–107CrossRefPubMedGoogle Scholar
  56. Pietrantonio F, Cremolini C, Aprile G, Lonardi S, Orlandi A (2015) Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: challenging drug label to light up new hope. Oncologist 20(11):1261–1265CrossRefPubMedPubMedCentralGoogle Scholar
  57. Pritchard KI, Burris HA, Ito Y, Rugo HS, Dakhil S et al (2013) Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer 13(6):421–432CrossRefPubMedGoogle Scholar
  58. Puts MT, Monette J, Girre V, Pepe C, Monette M, Assouline S, Panasci L, Basik M, Miller WH Jr, Batist G, Wolfson C, Bergman H (2011) Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study. Crit Rev Oncol Hematol 78(2):138–149CrossRefPubMedGoogle Scholar
  59. Radermacher J, Bokemeyer C (1999) Renale Toxizität. In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium internistische Onkologie. Springer, Berlin/Heidelberg/New YorkGoogle Scholar
  60. Riseberg D (2015) Treating elderly patients with hormone receptor-positive advanced breast cancer. Clin Med Insights Oncol 9:65–73CrossRefPubMedPubMedCentralGoogle Scholar
  61. Sant M, Minicozzi P, Mounier M et al (2014) Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol 15:931–942CrossRefPubMedGoogle Scholar
  62. Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091–1097CrossRefPubMedGoogle Scholar
  63. Schild SE, Stella PJ, Geyer SM et al (2003) The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 21:3201CrossRefPubMedGoogle Scholar
  64. Schütte J, Barth J (2010) Zytostatische Chemotherapie. In: Hiddemann W, Bartram CR (Hrsg) Onkologie. Springer, Berlin, S 401–436Google Scholar
  65. Sioka C, Kyritsis A (2009) Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 63:761–767CrossRefPubMedGoogle Scholar
  66. Smorenburg CH, de Groot SM, van Leeuwen-Stok AE, Hamaker ME, Wymenga AN, de Graaf H, de Jongh FE, Braun JJ, Los M, Maartense E, van Tinteren H, Nortier JW, Seynaeve C (2014) A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG. Ann Oncol 25(3):599–605CrossRefPubMedPubMedCentralGoogle Scholar
  67. Spina M, Balzarotti M, Uziel L, Ferreri AJ, Fratino L, Magagnoli M, Talamini R, Giacalone A, Ravaioli E, Chimienti E, Berretta M, Lleshi A, Santoro A, Tirelli U (2012) Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Oncologist 17:838–846CrossRefPubMedPubMedCentralGoogle Scholar
  68. Stamatoullas A, Brice P, Bouabdallah R, Mareschal S, Camus V, Rahal I, Franchi P, Lanic H, Tilly H (2015) Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol 170(2):179–184CrossRefPubMedGoogle Scholar
  69. Thyss A, Saudes L, Otto J, Creisson A, Gaspard MH, Dassonville O, Schneider M (1994) Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol 12(10):2121–2125CrossRefPubMedGoogle Scholar
  70. Van Cutsem E et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386–1422CrossRefPubMedGoogle Scholar
  71. Wedding U (2002) Zytostatische Therapie. In: Höffken K, Kolb G, Wedding U (Hrsg) Geriatrische Onkologie. Springer, Heidelberg, S 244–289Google Scholar
  72. Westfeld M, Liekweg A, Bornemann K, Scharfenberg H, Jaehde U (2006) Manuale zur pharmazeutischen Betreuung, Bd 8, Maligne Erkrankungen. Govi-Verlag, EschbornGoogle Scholar
  73. Wildiers H, Heeren P, Puts M et al (2014) International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 32:2595–2603CrossRefPubMedPubMedCentralGoogle Scholar
  74. Yilmaz M, Lahoti A, O’Brien S, Nogueras-González GM, Burger J, Ferrajoli A, Borthakur G, Ravandi F, Pierce S, Jabbour E, Kantarjian H, Cortes JE (2015) Estimated glomerular filtration rate changes in patient with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer 121(21):3894–3904CrossRefPubMedPubMedCentralGoogle Scholar
  75. Yoshida M et al (2016) Analysis of elderly patients with diffuse large B-cell lymphoma: aggressive therapy is a reasonable approach for unfit patients classified by comprehensive geriatric assessment. Eur J Haematol 96(4):409–416CrossRefPubMedGoogle Scholar
  76. Zaarour M, Weerasinghe C, Nazha B et al (2015) Epidermal growth factor receptor tyrosine kinase inhibitor in elderly patients with non-small lung cancer. Expert Rev Anticancer Ther 15(11):1327–1336CrossRefPubMedGoogle Scholar
  77. Zulman DM, Sussman JB, Chen X et al (2011) Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med 26:783–790CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Klinik für Innere Medizin 2Marien-HospitalWeselDeutschland

Section editors and affiliations

  • Matthias Ebert
    • 1
  1. 1.II. Medizinischen KlinikUniversitätsmedizin MannheimMannheimDeutschland

Personalised recommendations